Related Experiment Video
Updated: Feb 5, 2026

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
Published on: November 22, 2021
Does TMB Impact the Effectiveness of TKIs in EGFR-Mutant NSCLC?
Michael L Cheng1,2, Geoffrey R Oxnard3,2
1Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Abstract:
Patients with EGFR-mutant non-small cell lung cancer achieve variable benefit from targeted therapy, and biomarkers to predict degree of benefit are not in clinical use. EGFR-mutant cancers with high tumor mutational burden demonstrate poorer outcomes on EGFR-targeted therapy. Investigation into the mechanisms underlying this intriguing association is needed.See related article by Offin et al., p. 1063.
Related Concept Videos
Impact of Groups on Groups
Framing Effects
Impact
When particles with different initial velocities collide, they induce deformation by applying equal and opposite impulses. At the point of maximum deformation, the particles move together with...
Impact of Groups on Individuals
Impact of Individuals on a Group
Impact of Schemas

